Towards therapeutic base editing.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Base Editing of Human Hematopoietic Stem Cells.Methods in molecular biology (Clifton, N.J.) · 2023
   Article
2. Cytosine and adenine deaminase base-editors induce broad and nonspecific changes in gene expression and splicing.Communications biology · 2021
   Article
3. Future trends in synthetic biology in Asia.Advanced genetics (Hoboken, N.J.) · 2021
   Article
4. Therapeutic base editing of human hematopoietic stem cells.Nature medicine · 2020
   Article

Corrections and comments

• Comment on
  In utero CRISPR-mediated therapeutic editing of metabolic genes.2018
• Comment on
  Treatment of a metabolic liver disease by in vivo genome base editing in adult mice.2018

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as